文献速递肿瘤 PET/CT

胃腺癌疗效评估:⁶⁸Ga-FAPI-46与¹⁸F-FDG PET/CT不一致凸显肿瘤微环境在治疗抵抗中的作用

Response Assessment of Gastric Adenocarcinoma Using ⁶⁸Ga-FAPI-46 and 18 F-FDG PET/CT : Highlighting the Role of the Tumor Microenvironment in Therapy Resistance.
PubMed 文献 · Clin Nucl Med · 2026-05-04

本文报道一例71岁复发性胃腺癌女性患者,随访增强CT显示结肠壁受累。初始再分期¹⁸F-FDG PET/CT显示结肠和网膜强烈摄取,符合复发性恶性肿瘤。化疗后随访¹⁸F-FDG PET/CT显示代谢明显改善;但同期⁶⁸Ga-FAPI PET/CT显示结肠壁、腹膜和网膜持续强烈摄取,与先前¹⁸F-FDG PET/CT所见 closely 相似,并与持续临床恶化相关。这种不一致提示肿瘤细胞与癌相关成纤维细胞之间存在差异治疗反应,提出持续肿瘤微环境活性可能 underlying 治疗抵抗的假设,凸显FAP靶向策略与肿瘤导向治疗早期整合的潜在价值。

要点

  • 化疗后¹⁸F-FDG PET/CT代谢改善但⁶⁸Ga-FAPI PET/CT持续强烈摄取,提示肿瘤细胞与微环境差异反应。
  • FAPI持续摄取与临床恶化相关,提示肿瘤微环境活性可能参与治疗抵抗。
  • 结果支持早期整合FAP靶向策略与肿瘤导向治疗的潜在价值。

核心结论

  • ¹⁸F-FDG与⁶⁸Ga-FAPI PET/CT的不一致提示肿瘤细胞与癌相关成纤维细胞对化疗反应不同。
  • 持续肿瘤微环境活性可能 underlying 治疗抵抗。

研究设计与样本

  • 个案报道:一例71岁复发性胃腺癌女性患者。
  • 随访增强CT显示结肠壁受累后行¹⁸F-FDG PET/CT再分期。
  • 化疗后行¹⁸F-FDG PET/CT和⁶⁸Ga-FAPI PET/CT对比评估。

主要发现

  • 初始¹⁸F-FDG PET/CT显示结肠和网膜强烈摄取,符合复发性恶性肿瘤。
  • 化疗后¹⁸F-FDG PET/CT显示代谢明显改善。
  • 同期⁶⁸Ga-FAPI PET/CT显示结肠壁、腹膜和网膜持续强烈摄取,与先前¹⁸F-FDG PET/CT所见 closely 相似。
  • FAPI持续摄取与持续临床恶化相关。

临床怎么用

  • 对胃腺癌化疗后评估,可考虑联合FAPI PET/CT识别FDG代谢改善但微环境持续活性的患者。
  • FAPI持续摄取可能提示治疗抵抗,支持早期整合FAP靶向策略的潜在价值。

局限性

  • 仅为单例个案报道,结论需更大样本验证。
  • 未提供定量SUV、阈值或统计比较数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report a 71‑year‑old woman with recurrent gastric adenocarcinoma presenting with colonic wall involvement on follow-up contrast-enhanced CT scan. Initial restaging 18 F‑FDG PET/CT demonstrated intense colonic and omental uptake, consistent with recurrent malignancy. After chemotherapy, follow‑up 18 F-FDG PET/CT showed marked metabolic improvement; however, concurrent ⁶⁸Ga‑FAPI PET/CT revealed persistent intense uptake in the colonic wall, peritoneum, and omentum, closely resembling that observed on the prior 18 F-FDG PET/CT, correlating with ongoing clinical deterioration. This discordance suggests differential treatment response between tumor cells and cancer‑associated fibroblasts. Our findings raise the hypothesis that persistent tumor microenvironment activity may underlie therapeutic resistance, highlighting the potential value of early integration of FAP‑targeted strategies alongside tumor‑directed therapies.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sheikhnezami M, Samadi MH, Sadeghi R, et al. Response Assessment of Gastric Adenocarcinoma Using ⁶⁸Ga-FAPI-46 and 18 F-FDG PET/CT : Highlighting the Role of the Tumor Microenvironment in Therapy Resistance. Clin Nucl Med. 2026. PMID: 42113821. doi:10.1097/RLU.0000000000006519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。